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ABSTRACT
ObjeCtive
To evaluate the effectiveness of antenatal 
corticosteroids given at ≥34 weeks’ gestation.
Design
Systematic review with meta-analysis.
Data sOurCes
Electronic databases were searched from their 
inception to February 2016.
eligibility Criteria fOr stuDy seleCtiOn
Randomized clinical trials comparing antenatal 
corticosteroids with placebo or no treatment in women 
with a singleton pregnancy at ≥34 weeks’ gestation. 
Trials on antenatal steroids in women expected to 
deliver late preterm (340-366 weeks) and trials given 
before planned cesarean delivery at term (≥37 weeks) 
were included.
Data synthesis
The primary outcome was the incidence of severe 
respiratory distress syndrome (RDS). The summary 
measures were reported as relative risks or mean 
differences with 95% confidence intervals.
results
Six trials, including 5698 singleton pregnancies, were 
analyzed. Three included 3200 women at 340-366 
weeks’ gestation and at risk of imminent premature 
delivery at the time of hospital admission. The three 
other trials included 2498 women undergoing planned 
cesarean delivery at ≥37 weeks. Overall, infants of 
mothers who received antenatal corticosteroids at ≥34 
weeks had a significantly lower risk of RDS (relative 
risk 0.74, 95% confidence interval 0.61 to 0.91), mild 
RDS (0.67, 0.46 to 0.96), moderate RDS (0.39, 0.18 to 
0.89), transient tachypnea of the newborn (0.56, 0.37 
to 0.86), severe RDS (0.55, 0.33 to 0.91), use of 
surfactant, and mechanical ventilation, and a 
significantly lower time receiving oxygen (mean 
difference −2.06 hours, 95% confidence interval −2.17 
to −1.95), lower maximum inspired oxygen 
concentration (−0.66%, −0.69% to −0.63%), shorter 
stay on a neonatal intensive care unit (−7.64 days, 
−7.65 to −7.64), and higher APGAR scores compared 
with controls. Infants of mothers who received 
antenatal betamethasone at 340-366 weeks’ gestation 
had a significantly lower incidence of transient 
tachypnea of the newborn (relative risk 0.72, 95% 
confidence interval 0.56 to 0.92), severe RDS (0.60, 
0.33 to 0.94), and use of surfactant (0.61, 0.38 to 
0.99). Infants of mothers undergoing planned 
cesarean delivery at ≥37 weeks’ gestation who 
received prophylactic antenatal corticosteroids 48 
hours before delivery had a significantly lower risk of 
RDS (0.40, 0.27 to 0.59), mild RDS (0.43, 0.26 to 0.72), 
moderate RDS (0.40, 0.18 to 0.88), transient 
tachypnea of the newborn (0.38, 0.25 to 0.57), and 
mechanical ventilation (0.19, 0.08 to 0.43), and 
significantly less time receiving oxygen (mean 
difference −2.06 hours, 95% confidence interval −2.17 
to −1.95), lower percentage of maximum inspired 
oxygen concentration (−0.66%, −0.69% to −0.63%), 
shorter stay in neonatal intensive care (−7.44 days, 
−7.44 to −7.43), and a higher APGAR score at one and 
at five minutes.
COnClusiOns
Antenatal steroids at ≥34 weeks’ gestation reduce 
neonatal respiratory morbidity. A single course of 
corticosteroids can be considered for women at risk of 
imminent late premature delivery 340-366 weeks’ 
gestation, as well as for women undergoing planned 
cesarean delivery at ≥37 weeks’ gestation.
systematiC review registratiOn
PROSPERO CRD42016035234.
Introduction
Respiratory distress syndrome (RDS) is one of the most 
important causes of early neonatal morbidity and mor-
tality.1  In the United States it affects about 20% of low 
birthweight infants and 30% of extremely low birth-
weight infants.1  Infants born at late preterm, between 
34 and 36 weeks’ gestation, are more likely to experi-
ence respiratory complications than infants born at 
term. Cesarean delivery is also a risk factor for the 
development of neonatal respiratory complications, 
including RDS.1 2
Respiratory failure in these babies occurs as a result 
of surfactant deficiency, poor anatomical development 
of lung, as well as immaturity in other organs.2 
 Neonatal survival after preterm birth improves with 
length of gestation, reflecting improved maturity of 
organ systems.2
WhAT IS AlReAdy knoWn on ThIS TopIC
Prophylactic corticosteroids in preterm pregnancies accelerate lung maturation and 
reduce the incidence of respiratory morbidity
Use of antenatal corticosteroids is currently recommended at 24-33 weeks’ 
gestation in women at risk of preterm birth, whereas the evidence for use at or 
beyond 34 weeks is still debatable
WhAT ThIS STudy AddS
Use of antenatal steroids at 34 or more weeks’ gestation reduces neonatal 
respiratory morbidity
A single course of corticosteroids can be considered for women at risk of imminent 
late premature delivery, as well as for those undergoing planned cesarean at term
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Prophylactic corticosteroids in singleton preterm 
pregnancies accelerate lung maturation and reduce the 
incidence of RDS.3 Therefore, antenatal corticosteroids 
are currently recommended between 24 and 336 weeks’ 
gestation in women at risk of preterm birth within seven 
days—for example, in cases of threatened preterm 
labor, preterm premature rupture of membranes, ante-
partum hemorrhage.4 5  The evidence for use of antena-
tal steroids at or after 34 weeks is still debatable.3-5 
Recently, the American College of Obstetricians and 
Gynecologists recommended antenatal corticosteroids 
for women at risk of late premature delivery at greater 
than 34 weeks’ gestation but not for women undergoing 
planned cesarean at term;5 whereas according to the 
Royal College of Obstetricians and Gynaecologists ante-
natal corticosteroids should be given to all women with 
a planned elective cesarean section prior to 386 weeks’ 
gestation.4
In this systematic review and meta-analysis we eval-
uated the effectiveness of antenatal corticosteroids 
given at or after 34 weeks to reduce neonatal respiratory 
morbidity.
Methods
search strategy and selection criteria
This review was performed according to a protocol 
designed a priori and recommended for systematic 
reviews.6 We searched Medline, Scopus, ClinicalTrials.
gov, Embase, Sciencedirect, the Cochrane Library at the 
CENTRAL Register of Controlled Trials, Scielo from their 
inception to February 2016. Search terms used were: 
“cesarean”, “caesarean”, “steroids”, “corticosteroids”, 
“planned”, “elective”, “term”, “preterm”, “infants”, 
“respiratory”, “morbidity”, “mortality”, “meta-analy-
sis”, “metaanalysis”, “review”, “randomized”, “ran-
domised”, “effectiveness”, “antenatal”, “disorders”, 
“late”, and “clinical trial”. No restrictions for language 
or geographic location were applied. In addition, we 
examined the reference lists of all identified articles to 
find studies not captured by electronic searches. Two 
authors (GS, VB) independently assessed the electronic 
search and the eligibility of the studies. Differences 
were discussed and consensus reached.
We included all randomized controlled trials compar-
ing use of antenatal corticosteroids (intervention group) 
with placebo or no treatment (control group) in women 
with a singleton pregnancy at 34 or more weeks. We 
also included trials on use of antenatal steroids in both 
women expected to deliver in late preterm (340-366 
weeks) and women before planned cesarean delivery at 
term (≥37 weeks). Trials on prophylactic antenatal cor-
ticosteroids given at less than 34 weeks and those 
including multiple pregnancies and quasi-randomized 
trials (trials with allocation done on the basis of a pseu-
do-random sequence, such as odd or even hospital 
number or date of birth, alternation) were also 
excluded.
Data extraction and risk of bias assessment
To assess the risk of bias in each included study we used 
the criteria outlined in the Cochrane Handbook.6 
In each included trial we assessed seven domains related 
to risk of bias, as evidence suggests that these are associ-
ated with biased estimates of treatment effect: random 
sequence generation, allocation concealment, blinding 
of participants and staff, blinding of outcome assess-
ment, incomplete outcome data, selective reporting, and 
other bias. The review authors categorized studies as 
“low risk,” “high risk,” or “unclear risk” of bias.6
Two authors (GS, VB) independently assessed inclu-
sion criteria, risk of bias, and data extraction. Disagree-
ments were resolved by discussion.
We carried out all analyses using an intention to treat 
approach, evaluating women according to the treat-
ment group to which they were randomly allocated in 
the original trials. Primary and secondary outcomes 
were defined before data extraction. The primary out-
come was the incidence of severe RDS.7  Secondary out-
comes were incidence of overall RDS (mild, moderate, 
or severe);7  incidence of mild and moderate RDS;7  inci-
dence of transient tachypnea of the newborn;7 use of 
surfactant, mask ventilation, and mechanical ventila-
tion; time receiving oxygen (hours); maximum inspired 
oxygen concentration (%); incidence of admission to 
neonatal intensive care unit; length of stay in the neo-
natal intensive care unit (days); APGAR score at one 
and at five minutes; neonatal hypoglycemia (glucose 
<2.2 mmol/L); and neonatal mortality (defined as death 
of a liveborn baby within the first 28 days of life).
We separately assessed the primary and secondary 
outcomes in the main analysis as well as in studies on 
antenatal steroids in women expected to deliver late 
preterm (340-366 weeks) and in studies on antenatal ste-
roids given immediately before scheduled cesarean 
delivery at 37 or more weeks. We also planned to assess 
the primary outcome (incidence of severe RDS) in sensi-
tivity analysis according to the study design of the orig-
inal trial, excluding studies without placebo as control.
statistical analysis
Two authors (GS, VB) independently completed the 
data analysis using Review Manager v. 5.3. They com-
pared the completed analyses, and resolved any differ-
ences by discussion.
Using custom-made data collection forms, we 
extracted data from each eligible study without modifi-
cation of the original data. A 2×2 table was assessed for 
relative risk; for continuous outcomes means with or 
without standard deviations were extracted and 
imported into Review Manager v. 5.3.
Meta-analysis was performed using the random 
effects model of DerSimonian and Laird, to produce 
summary treatment effects in terms of either relative 
risks or mean differences, with 95% confidence inter-
vals. Heterogeneity was measured using the I2 statistic 
(Higgins I2). To account for the uncertainty in estimat-
ing heterogeneity, we converted DerSimonian and Laird 
results to Hartung and Knapp results, which accounts 
for the extra uncertainty.8
For individual trials with no events in one or both 
groups, we added a continuity correction of 0.5 to each 
cell for each effect measure.6
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Potential publication biases were assessed graphi-
cally by using a funnel plot of the primary outcome and 
statistically by using Begg’s and Egger’s tests. We con-
sidered a P value of less than 0.05 to be significant.
The meta-analysis was reported following the pre-
ferred reporting item for systematic reviews and 
meta-analyses (PRISMA) statement.9  Before data 
extraction, we registered the review with PROSPERO 
following the PRISMA guidelines for protocols (registra-
tion number CRD42016035234).10
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design, or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community.
Results
Figure 1  shows the flow of study identification. Supple-
mentary file S1 details the full electronic search. Six tri-
als, including 5698 singleton pregnancies, were 
identified as relevant and included in the meta- 
analysis.11-16  Data were also obtained by a follow-up of a 
randomized controlled trial.17 Publication bias could not 
be assessed for all the different outcomes, given the 
small (<10) number of studies included.
Most of the included studies (four out of the six),13 15 
were judged as low risk of bias in most of the seven 
Cochrane domains related to the risk of bias. All the 
included studies had low risk of bias in random 
sequence generation. Adequate methods for allocation 
of women were used in all the included trials, except 
two in which details on methods used to conceal alloca-
tion were not reported.13 16  In three double blind stud-
ies,12 14 16  neither the participants nor the investigators 
were aware of the treatment assignments. Three trials 
were judged as low risk of bias for incomplete outcome 
data,11 12 14  two as unclear,13 15  and one as high risk16  (figs 
2  and 3). Supplementary file S2 shows the details of the 
risk of bias assessment for each included study.
Table 1  shows the characteristics of the included clin-
ical trials. All six studies excluded multiple pregnan-
cies. Four trials used betamethasone as 
corticosteroid11 12 14 15  and two used dexamethasone.13 16 
Three trials used placebo as control.11 14 16  In all of the 
included studies but two,15 16  corticosteroids were given 
intramuscularly in two doses of 12 mg separated by 24 
hours. The first trial used a single dose of 12 mg antena-
tal betamethasone.15  In the other trial, the intervention 
group consisted of 645 women who received intramus-
cular dexamethasone 8 mg every 12 hours for two days, 
48 hours before planned cesarean delivery.16 None of 
the trials assessed compliance to the treatment.
Three trials included 2498 women undergoing 
planned cesarean delivery at 37 or more weeks.11 13 16 The 
other three studies included 3200 women at 340-366 
weeks’ gestation and at risk of imminent late premature 
delivery (spontaneously or as indicated) at the time of 
admission to hospital.12 14 15 High probability of delivery 
in late preterm period (340-366 weeks) included any one 
of the following: membrane rupture; preterm labor with 
intact membranes, defined as at least six regular uter-
ine contractions in an observation period of no more 
than 60 minutes and cervix either greater than or equal 
to 3 cm dilated or 80% effaced; planned delivery by 
induction of labor or cesarean scheduled by 366 weeks’ 
gestation at the latest for any indication, including prior 
myomectomy, prior classic cesarean, intrauterine 
growth restriction, pre-eclampsia, oligohydramnios, 
non-reassuring fetal heart rate tracing warranting 
delivery, placental abruption, or placenta previa. The 
US trial excluded women with pregestational diabetes 
Records identied through database searching (n=167)
Records screened aer duplicates removed (n=150)
Studies included in qualitative synthesis (n=6)
Full text articles assessed for eligibility (n=26)
Studies included in quantitative synthesis (meta-analysis) (n=6)
Records excluded based on title and abstract (n=9)
Full text articles excluded (n=20):
  Duplicates (n=1)
  Antenatal steroids <34 weeks (n=19)
fig 1 | flow diagram of studies identified in systematic review
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fig 2 | summary of risk of bias for each trial. green=low risk 
of bias; red=high risk of bias; yellow=unclear risk of bias
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and women who previously received a course of cortico-
steroids. Tocolysis was not employed as part of this 
trial, and delivery was not delayed for obstetric or med-
ical indications.14
RDS was defined in the studies as the presence of 
clinical signs of respiratory distress with an oxygen 
requirement and a chest radiograph showing reticu-
logranular infiltrates.7  Transient tachypnea of the new-
born was defined as respiratory distress without diffuse 
reticulogranular infiltrate resolved spontaneously by 72 
hours of age.7
In three trials, incidence of RDS was the primary out-
come;12 13 15  in two trials, incidence of admission to a 
neonatal intensive care unit was the primary out-
come;11 16  whereas the US trial defined the primary out-
come as a composite endpoint describing the need for 
respiratory support by 72 hours of age and consisted of 
one or more of the following: continuous positive air-
way pressure or high flow nasal cannula for at least two 
consecutive hours, an oxygen requirement with a frac-
tion of inspired oxygen of at least 30% for at least four 
continuous hours, extracorporeal membrane oxygen-
ation, or the need for mechanical ventilation.14
Table 2  shows primary and secondary outcomes in the 
main analysis. Women who received prophylactic ante-
natal corticosteroids (betamethasone or dexametha-
sone) after 34 weeks had a significantly lower incidence 
of RDS (relative risk 0.74, 95% confidence interval 0.61 to 
0.91; fig 4 ), mild RDS (0.67, 0.46 to 0.96), moderate RDS 
(0.39, 0.18 to 0.89), transient tachypnea of the newborn 
(0.56, 0.37 to 0.86; fig 5 ), severe RDS (0.55, 0.33 to 0.91; 
fig 6), use of surfactant (0.61, 0.38 to 0.99), use of mechan-
ical ventilation (0.52, 0.36 to 0.76), significantly lower 
time receiving oxygen (mean difference −2.06 hours, 95% 
confidence interval −2.17 to −1.95), lower maximum 
inspired oxygen concentration (−0.66%, −0.69 to −0.63), 
lower length of stay in the neonatal intensive care unit 
(−7.64 days, −7.65 to −7.64), higher APGAR score at one 
and at five minutes (0.06, 0.05 to 0.07), and higher neo-
natal hypoglycemia (1.61, 1.38 to 1.87) compared with 
those who did not. After converting results using the Har-
tung and Knapp approach, use of surfactant was no lon-
ger significant. No statistically significant differences 
were found in use of mask  ventilation (relative risk 0.85, 
95% confidence interval 0.69 to 1.04), admission to a neo-
natal intensive care unit (0.81, 0.54 to 1.20), and neonatal 
death (0.77, 0.21 to 2.83).
Table 3 shows the primary and secondary outcomes in 
women at risk of late premature delivery (340-366 weeks). 
Women who received antenatal betamethasone at 340-
366 weeks’ gestation had a significantly lower incidence 
of transient tachypnea of the newborn (0.72, 0.56 to 
0.92), severe RDS (0.60, 0.33 to 0.94), and use of surfac-
tant (0.61, 0.38 to 0.99,) but higher neonatal hypoglyce-
mia (1.61, 1.38 to 1.87). After converting results using the 
Hartung and Knapp approach, use of surfactant was no 
longer significant. No statistically significant differences 
were found in the incidence of overall RDS (0.98, 0.77 to 
1.24), mild RDS (1.09, 0.66 to 1.80), mask ventilation 
(0.83, 0.67 to 1.02), mechanical ventilation (0.80, 0.51 to 
1.24), admission to a neonatal intensive care unit (0.94, 
0.87 to 1.02), APGAR score at one minute (mean differ-
ence −0.46, 95% confidence interval −0.78 to 0.14) and at 
five minutes (−0.62, −0.91 to 0.33), and neonatal death 
(relative risk 0.95, 95% confidence interval 0.20 to 4.58).
In sensitivity analysis according to study design of 
the included trials, excluding one study,15  we found 
that women at risk of late premature delivery who 
received antenatal corticosteroids at 34 or more weeks 
still had a significantly lower risk of the primary out-
come (incidence of severe RDS) in the pooled data from 
only trials that used placebo as control (0.67, 0.54 to 
0.84; table 4 ).12 14
Table 5 shows the primary and secondary outcomes 
in women undergoing scheduled cesarean delivery at 
term. Women undergoing planned cesarean delivery at 
370 or more weeks who received prophylactic antenatal 
corticosteroids (betamethasone or dexamethasone) 48 
hours before delivery had a significantly lower risk of 
RDS (0.40, 0.27 to 0.59), mild RDS (0.43, 0.26 to 0.72), 
moderate RDS (0.40, 0.18 to 0.88), transient tachypnea 
of the newborn (0.38, 0.25 to 0.57), mechanical ventila-
tion (0.19, 0.08 to 0.43), significantly lower time receiv-
ing oxygen (mean difference −2.06 hours, 95% 
confidence interval −2.17 to −1.95), lower percentage of 
maximum inspired oxygen concentration (−0.66%, 
−0.69 to −0.63), lower length of stay in the neonatal 
intensive care unit (−7.44 days, −7.44 to −7.43), and 
higher APGAR scores at one and five minutes (0.06, 0.07 
to 0.05). We found no statistically significant differences 
in number of fetuses who required mask ventilation 
(relative risk 1.06, 95% confidence interval 0.53 to 2.08), 
in the incidence of admission to the neonatal intensive 
care unit (0.48, 0.19 to 1.20), and in the incidence of 
neonatal death (0.50, 0.05 to 5.46).
discussion
This meta-analysis of the findings from six randomized 
controlled trials,11-16 including 5698 singleton pregnan-
cies, evaluated the efficacy of prophylactic antenatal 
corticosteroids (betamethasone or dexamethasone) 
given at or after 34 weeks. Our findings showed that 
antenatal steroids administered at 34 or more weeks’ 
gestation reduce neonatal respiratory morbidity.
Percentage
0 20 40 60 80 100
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Low risk of bias Unclear risk of bias High risk of bias
fig 3 | risk of bias item presented as percentages across all included studies. green=low 
risk of bias; red=high risk of bias; yellow=unclear risk of bias
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Our meta-analysis showed neonatal benefit of ante-
natal betamethasone in women at immediate risk of 
late preterm delivery (340-366 weeks). A single course of 
antenatal corticosteroids given immediately before 
planned cesarean delivery at 37 or more weeks’ gesta-
tion was also associated with a reduction in the rates of 
mild, moderate, and severe respiratory distress syn-
drome (RDS). Out of the three trials included, one 
enrolled women undergoing planned cesarean delivery 
at 370-396 weeks’ gestation,13  one enrolled women at 37 
weeks or beyond,11 and one enrolled women at 380-386 
weeks.16  Another study also found that the rate of RDS 
decreased with increasing gestation, supporting the 
recommendation to delay planned cesarean delivery 
until the 39th week.11
Comparison with other studies
Two current Cochrane reviews have reported data on 
the effects of antenatal corticosteroids.3 18  The first 
meta-analysis aimed to assess the effects on fetal and 
neonatal morbidity and mortality of administering cor-
ticosteroids to the mother before anticipated preterm 
delivery.3  The evidence from this meta-analysis sup-
ported the continued use of a single course of antenatal 
corticosteroids to accelerate fetal lung maturation in 
women at risk of preterm birth of less than 34 weeks’ 
gestation. However they did not evaluate the effective-
ness of antenatal corticosteroids given at or after 34 
weeks.3  The second meta-analysis,18  including only 
one trial (942 participants),13 showed that antenatal ste-
roids did not prevent RDS compared with no treatment 
in women undergoing planned cesarean delivery at 37 
or more weeks’ gestation.
strengths and limitations of this review
Our study has several strengths. The six trials included 
had a low risk of allocation bias by Cochrane Collabora-
tion tool assessment. An intention to treat analysis was 
used. To our knowledge, no prior meta-analysis on this 
issue is as large, up to date, or comprehensive.
Limitations of our study are mostly inherent to the 
limitations of the included studies. Only three trials 
used placebo as control and were double blind. Data on 
optimal dose to delivery interval and optimal corticoste-
roid to use were limited. Almost half of the women 
included in the analysis (2831 out of the 5698) came 
from one large well designed trial.14  Performing sub-
group analysis by mode of delivery in the late preterm 
group was not feasible. The major shortcoming was the 
lack of data on long term outcomes. Only one trial 
reported long term follow-up,17  so the long term safety 
of antenatal corticosteroids at late preterm or term is 
still not well known. One trial reported that antenatal 
betamethasone did not result in any adverse long term 
neurological or cognitive outcomes at age 8-15 years.17
interpretation of the findings
Dexamethasone and betamethasone are the two ante-
natal corticosteroids recommended for accelerating 
fetal lung development in threatened preterm 
birth.3-5   The American College of Obstetricians and t
ab
le
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7
 Gynecologists and Royal College of Obstetricians and 
Gynaecologists list both as effective drugs for prevent-
ing complications of prematurity, using either a dosage 
of 24 mg dexamethasone (four 6 mg doses 12 hours 
apart) or 24 mg betamethasone (two 12 mg doses 24 
hours apart).4 5  In a 2013 Cochrane Review, evaluating 
the effects of different corticosteroid regimens for 
women at risk of preterm birth, the reviewers concluded 
that “It remains unclear whether one corticosteroid (or 
one particular regimen) has advantages over another.”19
A single course of antenatal corticosteroids should be 
considered routine for women at less than 34 weeks’ 
gestation for risk of preterm birth,3 whereas so far evi-
dence for administering antenatal steroids at or after 34 
weeks is still debatable. Our meta-analysis based on 
level 1 data showed that antenatal corticosteroids after 
34 weeks’ gestation improved neonatal outcomes.
The biological plausibility to explain our findings 
may be different in women undergoing scheduled 
cesarean delivery at term and in women at risk of late 
preterm delivery.
Cesarean delivery is a risk factor for the development 
of neonatal respiratory complications, mostly RDS and 
transient tachypnea of the newborn, in infants both at 
term and preterm.20 21 Infants born at term by cesarean 
delivery are more likely to develop respiratory morbid-
ity than infants born vaginally, and this risk increases 
further for the subgroup of children born after sched-
uled cesarean section—that is, before onset of labor 
with potentially severe implications. The risk decreases 
with advancing gestational age, and infants born at 
370-376 weeks’ gestation are at 1.7 times more risk for 
respiratory complications than those born at 380-386 
weeks’ gestation who in turn are at 2.4 times more risk 
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than the infants born at 390-396 weeks’ gestation.20  This 
trend is particularly pronounced for RDS.21  Respiratory 
morbidity in term planned cesarean delivery seems to 
have a different pathophysiology from that in preterm 
birth, with lack of the physiological catecholamine 
surge22 23  and fluid retention in the lungs24 25  being the 
most likely causes.22-25  Interestingly, recent evidence 
indicates that, apart from the mechanical concept of 
vaginal squeeze, molecular mechanisms (lung epithe-
lial sodium channels) promote alveolar fluid drainage, 
and these channels may be underactive in fetuses not 
exposed to the process of labor.22-25  Glucocorticoids 
appear to increase the number and function of sodium 
channels as well as the responsiveness to catechol-
amine and thyroids hormones, providing a rationale for 
their exogenous use in planned cesarean deliveries.22-25 
In view of this evidence, it is currently recommended 
that planned cesarean delivery should be deferred to 39 
weeks’ gestation.26 27  However, in the USA approxi-
mately 10-15% of women planned for cesarean might 
deliver before 39 weeks and there may be concerns on 
waiting in the presence of specific clinical indications 
or  history.1  Some have referred to planned cesarean 
delivery as “elective,” but we prefer avoiding this term, 
as it lacks the necessary scientific specificity.28  The 
American College of Obstetricians and Gynaecologists 
advises against “elective delivery” before 39 weeks’ ges-
tation.23  The challenge in this situation is that there is 
often lack of clarity between planned (scheduled) deliv-
ery and an elective delivery. Cesarean delivery sched-
uled at 35 weeks’ gestation because of placenta previa 
and suspected accreta is not an “elective” early preterm 
birth, and an increase in maternal-fetal morbidity has 
been associated with allowing such a pregnancy to con-
tinue beyond 36 weeks’ gestation.29
Infants born at late preterm, between 34 and 36 
weeks’ gestation, are more likely to experience respira-
tory complications than infants born at term.30 Our find-
ings suggested that antenatal betamethasone in women 
at immediate risk of late preterm delivery (340-366 
weeks) improves neonatal outcomes.
Notably, our meta-analysis also showed an increased 
risk of neonatal hypoglycemia, in women who were ran-
domized to antenatal corticosteroids at more than 34 
weeks’ gestation. Therefore, an important question is 
whether the short term benefits showed by this 
meta-analysis might be associated with any long term 
benefits or risks. In this context, the increase in the inci-
dence of neonatal hypoglycemia is particularly worri-
some, especially since neonatal hypoglycemia has been 
reported to be the only independent risk factor for later 
developmental delay and physical growth deficits 
among moderate or late preterm infants.31  However, no 
adverse events related to hypoglycemia were reported 
in any trials and the rates of hypoglycemia found are 
similar to what is reported in the general population of 
late preterm infants.14 31
Conclusions
Prophylactic antenatal corticosteroids given immedi-
ately before planned cesarean delivery at 37 or more t
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9
weeks’ gestation are effective in reducing RDS. There-
fore, in planned cesareans of infants at term, the risk of 
respiratory morbidity should be considered and the 
likely benefits of antenatal steroids compared with 
those of delaying delivery until 39 weeks’ gestation 
when possible. Delivery by scheduled cesarean delivery 
should be delayed until the 39th week whenever possi-
ble to reduce the risk of respiratory morbidity. When it 
is necessary to deliver by prelabor at 370-386 weeks’ ges-
tation, parents can be counseled about the benefits of a 
single course of antenatal corticosteroids, such as a 
reduction in RDS from 6.7% (86/1281) to 2.7% (33/1217) 
(table 5).
Prophylactic betamethasone is also beneficial in 
decreasing neonatal respiratory morbidities (such as 
severe RDS, from 2.3% (35/1530) to 1.4% (22/1570) (table 3)) 
in women at risk of imminent late premature delivery 
(340-366 weeks’ gestation). Tocolysis should not be used in 
order to delay delivery to allow for administration of late 
preterm antenatal corticosteroids, nor should an indicated 
late preterm delivery (such as for pre-eclampsia with 
severe features) be postponed for steroid administration.
In conclusion, a single course of corticosteroids 
(either two 12 mg doses of betamethasone given intra-
muscularly 24 hours apart or four 6 mg doses of dexa-
methasone administered intramuscularly every 12 
hours) should be considered for women undergoing 
planned cesarean at 37 or more weeks’ gestation as well 
as for women at risk of imminent late premature deliv-
ery at 340-366 weeks’ gestation.
Further studies are required on the optimal dose to 
delivery interval, optimal corticosteroid to use, effects 
in multiple pregnancies, long term effects into adult-
hood, as well as in groups not well studied, including 
women with pregestational diabetes and those who pre-
viously had received a course of corticosteroids.
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